- Home
- RSLS vs NUWE Comparison
RSLS vs NUWE Comparison
Compare RSLS & NUWE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RSLS
- NUWE
- Stock Information
- Founded
- RSLS 2002
- NUWE 1999
- Country
- RSLS United States
- NUWE United States
- Employees
- RSLS N/A
- NUWE N/A
- Industry
- RSLS Medical/Dental Instruments
- NUWE Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- RSLS Health Care
- NUWE Health Care
- Exchange
- RSLS Nasdaq
- NUWE Nasdaq
- Market Cap
- RSLS 4.5M
- NUWE 3.9M
- IPO Year
- RSLS 2007
- NUWE N/A
- Fundamental
- Price
- RSLS $2.39
- NUWE $6.88
- Analyst Decision
- RSLS Hold
- NUWE Strong Buy
- Analyst Count
- RSLS 1
- NUWE 1
- Target Price
- RSLS N/A
- NUWE $714.00
- AVG Volume (30 Days)
- RSLS 4.4M
- NUWE 123.4K
- Earning Date
- RSLS 08-13-2025
- NUWE 08-12-2025
- Dividend Yield
- RSLS N/A
- NUWE N/A
- EPS Growth
- RSLS N/A
- NUWE N/A
- EPS
- RSLS N/A
- NUWE N/A
- Revenue
- RSLS $7,175,000.00
- NUWE $8,787,000.00
- Revenue This Year
- RSLS $52.80
- NUWE $6.53
- Revenue Next Year
- RSLS N/A
- NUWE $51.63
- P/E Ratio
- RSLS N/A
- NUWE N/A
- Revenue Growth
- RSLS N/A
- NUWE N/A
- 52 Week Low
- RSLS $2.23
- NUWE $6.73
- 52 Week High
- RSLS $347.86
- NUWE $197.40
- Technical
- Relative Strength Index (RSI)
- RSLS 38.10
- NUWE 25.34
- Support Level
- RSLS $2.37
- NUWE $7.20
- Resistance Level
- RSLS $2.73
- NUWE $10.08
- Average True Range (ATR)
- RSLS 0.17
- NUWE 0.99
- MACD
- RSLS 0.21
- NUWE 0.64
- Stochastic Oscillator
- RSLS 13.33
- NUWE 10.66
About RSLS ReShape Lifesciences Inc.
Reshape Lifesciences Inc is a medical device company focused on technologies to treat obesity and metabolic diseases. The company's current portfolio includes the LAP-BAND, an Adjustable Gastric Banding System, ReShapeCare virtual health coaching program, ReShape Market Place, including ReShape Optimize a supplemental multivitamin, the Obalon Balloon System, the first and only swallowable gas-filled balloon system, and the Diabetes Bloc-Stim Neuromodulation, a technology under development as a new treatment for type 2 diabetes mellitus. Geographically, the company operates in the United States, Australia, Europe, and the Rest of world, and the majority of its revenue is generated from the United States.
About NUWE Nuwellis Inc.
Nuwellis Inc is a medical technology company focused on developing, manufacturing, and commercializing a medical device used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Nuwellis has one reportable segment: fluid overload.